Shares of Hyperfine, Inc. (NASDAQ:HYPR – Get Free Report) have earned an average rating of “Hold” from the five research firms that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and two have assigned a buy recommendation to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $1.45.
HYPR has been the topic of a number of research reports. Zacks Research raised shares of Hyperfine to a “hold” rating in a research note on Thursday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Hyperfine in a research report on Thursday, January 22nd. Finally, Lake Street Capital upped their target price on Hyperfine from $2.00 to $2.50 and gave the stock a “buy” rating in a report on Thursday.
Institutional Investors Weigh In On Hyperfine
Hyperfine Stock Up 2.5%
Shares of HYPR stock opened at $1.24 on Friday. The stock has a fifty day moving average of $1.15 and a 200 day moving average of $1.20. Hyperfine has a 52 week low of $0.53 and a 52 week high of $2.22. The firm has a market capitalization of $120.49 million, a price-to-earnings ratio of -2.82 and a beta of 1.09.
Hyperfine (NASDAQ:HYPR – Get Free Report) last issued its quarterly earnings data on Wednesday, March 18th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.02. Hyperfine had a negative net margin of 262.29% and a negative return on equity of 95.09%. The business had revenue of $5.29 million for the quarter, compared to the consensus estimate of $5.30 million. Equities research analysts anticipate that Hyperfine will post -0.57 earnings per share for the current year.
About Hyperfine
Hyperfine, Inc (NASDAQ: HYPR) is a medical technology company focused on expanding access to advanced neuroimaging through its portable magnetic resonance imaging (MRI) system. The company’s flagship product, Swoop®, is designed to enable bedside MRI scanning in a wide range of clinical environments, including emergency departments, intensive care units and outpatient clinics. By leveraging a compact, high-performance permanent magnet and a custom-designed gradient system, Hyperfine aims to reduce the logistical and financial barriers associated with traditional, large-scale MRI installations.
The Swoop system features a lightweight, wheeled design that can be maneuvered directly to a patient’s bedside, allowing clinicians to conduct diagnostic imaging without the need to transport critically ill or immobile patients.
Read More
Receive News & Ratings for Hyperfine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hyperfine and related companies with MarketBeat.com's FREE daily email newsletter.
